Table 2.

Anchor‐scale correlations based on change from baseline to mid‐treatment and change from baseline to end of treatment

Anchor measure	Definition (Improvement/Stable/Deterioration) (Stable/Deterioration for AE anchors)	Number improved/stable/deteriorated at MT	Correlation MT	Number improved/stable/deteriorated at EOT	Correlation EOT
GHS/QOL	+8.3/ 0/ −8.332	Improvement: 209 Stable: 465 Deterioration: 220	DS: −0.076 SE: −0.082 BI: 0.031 FP: 0.081	Improvement: 95 Stable: 227 Deterioration: 98	DS: −0.036 SE: −0.082 BI: 0.095 FP: 0.114
FACT‐GOG‐Ntx Additional Concerns	≥3.3/ 0/ ≤−3.333	Improvement: 222 Stable: 789 Deterioration: 333	DS: −0.410 SE: −0.545 BI: 0.299 FP: 0.227	Improvement: 85 Stable: 343 Deterioration: 250	DS: −0.416 SE: −0.607 BI: 0.336 FP: 0.314
ECOG PS	−1/ 0/ +134	Improvement: 210 Stable: 952 Deterioration: 299	DS: −0.135 SE: −0.124 BI: 0.011 FP: 0.030	Improvement: 87 Stable: 616 Deterioration: 231	DS: −0.171 SE: −0.226 BI: 0.101 FP: 0.149
Matched grade 2 + AEsa	None within MT/EOT window/ ≥1 within MT/EOT window35	Stable (DS): 1941 Deterioration (DS): 79 Stable (FP): 1992 Deterioration (FP): 28 Stable (SE): 1865 Deterioration (SE): 155	DS: −0.188 SE: −0.160 FP: 0.040	Stable (DS): 1025 Deterioration (DS): 27 Stable (FP): 1045 Deterioration (FP): 7 Stable (SE): 1016 Deterioration (SE): 36	DS: −0.196 SE: −0.322 FP: 0.044
Peripheral Neuropathy grade 2 + AEs	None within MT/EOT window/ ≥1 within MT/EOT window35	Stable: 1261 Deterioration: 84	DS: −0.029 SE: −0.271 BI: 0.096 FP: 0.035	Stable: 662 Deterioration: 16	DS: 0.124 SE: −0.235 BI: −0.042 FP: −0.060

Correlations in bold are ≥0.3 and thus retained for anchor‐based analyses on the scale of interest.

Abbreviations: AE, Adverse event; BI, Body image; DS, Disease Symptoms; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EOT, End of treatment; FP, Future perspective; GHS/QOL, Global Health Status/Quality of Life; MT, mid‐treatment; SE, Side Effects of treatment

^aMatched AEs for each scale are as follows: Disease Symptoms (DS: Chest pain, Back pain, Arthralgia, Bone pain, Pain in extremity, Musculoskeletal chest pain, Myalgia, Neuralgia); Future Perspective (FP: Anxiety, Insomnia); Side Effects of Treatment (SE: Fatigue, Paresthesia, Neuropathy peripheral, Polyneuropathy, Insomnia, Anxiety, Conjunctivitis, Chest pain, Dyspepsia). No AEs corresponding to the Body Image scale were identified.